LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate ...Middle East

- News
LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate
Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

Read More Details
Finally We wish PressBee provided you with enough information of ( LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate )

Apple Storegoogle play

Also on site :

Most viewed in News